Cinqair Or Cinqaero Market Report 2026

Cinqair Or Cinqaero Market Overview

• The Cinqair Or Cinqaero market growth in the historic period has been driven by limitations of corticosteroid therapies, identification of eosinophilic asthma phenotypes • Market expansion is supported by increasing asthma prevalence, personalized respiratory care approaches • Growth Driver: Impact of Air Pollution on Cinqair (Cinqaero) Market Growth • North America was the largest region in 2025 and Europe is the fastest growing region.

What Is Covered Under Cinqair Or Cinqaero Market?

Cinqair (also known as cinqaero) refers to reslizumab, a humanized monoclonal antibody used primarily for the treatment of severe eosinophilic asthma in adults. It works by targeting and inhibiting interleukin-5 (IL-5), a key regulator of eosinophil production, it effectively reduces eosinophil levels and inflammation in the body. The main clinical indications in the cinqair or cinqaero market are severe eosinophilic asthma. Severe eosinophilic asthma refers to a subtype of asthma characterized by high levels of eosinophils, a type of white blood cell that contributes to inflammation in the airways. The various applications include children, adults, and teenagers, and used by several end uses including hospitals, clinics, ambulatory care, and home care.

What Is The Cinqair Or Cinqaero Market Growth Forecast?

The growth in the forecast period can be attributed to increasing asthma prevalence, personalized respiratory care approaches, expansion of biologic reimbursement, improved patient stratification, growing pulmonology specialty networks. Major trends in the forecast period include growth of targeted biologics for severe asthma, shift toward il 5 inhibitor therapies, rising diagnosis of eosinophilic asthma, expansion of hospital based infusion treatments, focus on reducing asthma exacerbations.

Global Cinqair Or Cinqaero Market Segmentation

1) By Clinical Indication: Severe Eosinophilic Asthma, Uncontrolled Severe Eosinophilic Asthma, IL-5–Mediated Eosinophilic Asthma, Refractory Eosinophilic Asthma 2) By Application: Children, Adults, Teenagers 3) By End Use: Hospitals, Clinics, Ambulatory Care, Home Care

What Are The Drivers Of The Cinqair Or Cinqaero Market?

Increasing air pollution is expected to propel the growth of the cinqair or cinqaero market going forward. Air pollution refers to the contamination of the air by harmful substances such as gases, particles, and biological molecules, which can negatively impact human health and the environment. Increasing air pollution is primarily due to the burning of fossil fuels, industrial emissions, vehicle exhaust, and agricultural activities. Cinqair or cinqaero helps mitigate the impact of air pollution by improving lung function and reducing inflammation, which can enhance overall respiratory health and reduce the strain on healthcare systems often exacerbated by environmental pollutants. For instance, in May 2025, according to the U.S. Environmental Protection Agency (EPA), a US-based federal agency, roughly 66 million tons of pollutants were released into the United States atmosphere in 2023. Therefore, the increasing air pollution is driving the growth of the cinqair or cinqaero industry. Rise in demand for biological products is expected to propel the growth of the cinqair or cinqaero market going forward. Biological products refer to complex pharmaceutical substances derived from living organisms, used to diagnose, prevent, treat, and cure diseases and medical conditions. Biological products are attributed to growing environmental concerns, heightened consumer awareness, and the need for sustainable and effective alternatives to synthetic chemicals. Biologics like Cinqair (Cinqaero) help by targeting specific immune system components, such as interleukin-5 (IL-5), which play a key role in eosinophilic asthma, reducing inflammation in the airways and improving respiratory function in patients, especially those whose asthma is triggered by environmental factors like air pollution or allergens. For instance, in August 2025, according to the Assistant Secretary for Planning and Evaluation, a US-based government department, net revenue for biosimilars can span from a USD 33.5 million loss in smaller markets to USD 9.5 billion in larger ones, and proposed regulatory changes including universal interchangeability, a global comparator, and removal of comparative efficacy studies are estimated to cut development costs and raise lifetime revenues by USD 2 billion, USD 13.5 million, and USD 84 million, respectively. Therefore, the rise in demand for biological products is driving the growth of the cinqair or cinqaero industry. Increasing prevalence of asthma is expected to propel the growth of the cinqair or cinqaero market going forward. Asthma is attributed to a combination of genetic and environmental factors, including family history, allergies, respiratory infections during childhood, air pollution, and exposure to triggers such as pollen, dust mites, and tobacco smoke. Cinqair or cinqaero helps asthma patients by targeting and inhibiting interleukin-5 (IL-5), a key protein involved in the inflammatory process of eosinophilic asthma, thus reducing airway inflammation, improving lung function, and decreasing asthma exacerbations triggered by allergens or environmental factors like air pollution. For instance, in July 2024, the American Lung Association, a US-based voluntary health organization, reported that Black individuals had a current asthma rate of 10.3% in 2022 44 percent higher than the 8.4% rate among white individuals while adult asthma prevalence in 2023 varied widely, ranging from 7.1 percent in Mississippi to 14.1 percent in Puerto Rico. Thus, increasing prevalence of asthma is driving the growth of the cinqair or cinqaero industry.

Key Players In The Global Cinqair Or Cinqaero Market

Major companies operating in the cinqair or cinqaero market are Teva Pharmaceuticals

Regional Insights

North America was the largest region in the cinqair or cinqaero market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Cinqair Or Cinqaero Market?

The cinqair or cinqaero market consists of sales of reslizumab in forms such as intravenous solutions, single-use vials, and pre-mixed infusions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cinqair Or Cinqaero Market Report 2026?

The cinqair or cinqaero market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cinqair or cinqaero industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.